The NHS in England has approved the use of Fampridine, a drug that aids individuals with multiple sclerosis (MS) in improving their mobility.This medication works by enhancing nerve signals, enabling better movement and independence.

Aysen Slack, a patient who previously paid privately for the drug due to its high cost, welcomed the decision as it would significantly improve her quality of life.Up to 5,000 people in England could benefit annually from this treatment, which is already available in other UK regions.MS occurs when the immune system attacks myelin, damaging nerve pathways and impairing muscle control.Clinical trials showed that around 40% of patients experienced improved walking speed and endurance.

NHS officials emphasized that even modest improvements can enhance daily living, such as independent movement within homes or greater confidence in social settings.Eligibility is based on the severity of walking difficulties, with patients required to demonstrate clear benefits after a month of treatment.Experts highlighted the drug's potential to transform lives, allowing individuals to maintain independence and remain employed.